Study Finds Genomic Changes in the Brains of People Who Commit Suicide
New study published in Biological Psychiatry
New study published in Biological Psychiatry
Philadelphia, PA, October 23, 2008 – Are genes destiny? Alternatively, are we simply the products of our environment? There is a growing sense that neither of these two possibilities fully captures the essence of the risk for psychiatric disorders. New light is being shed on the complex interaction of genetic and environmental factors as the result of growth in the field of epigenetics. While genetics is the study of how variation in gene sequence or “genotype” influences traits or “phenotypes,” epigenetics (epi- from the Greek meaning outside or above) is the study of heritable changes in gene function that may occur without modifying the gene sequence, often as a consequence of environmental exposures.
There are an increasing variety of epigenetic mechanisms that have been described, including the regulation of gene function via the methylation or demethylation of DNA. The study by Drs. Michael Poulter and Hymie Anisman and colleagues in the October 15th issue of Biological Psychiatry illustrates one exciting new example in this area of research, an epigenetic study of depression/suicide. The researchers compared the brain tissues of those who had major depressive disorder and committed suicide to those from a control group who died suddenly, from heart attacks and other causes.
They found the genome in people who have committed suicide as a result of major depression was being chemically modified by a process that is normally involved in regulating cell development. As Poulter explains, “We have about 40,000 genes in every cell and the only reason a skin cell becomes a skin cell as opposed to a heart cell is because only a fraction of the genes are being expressed, and the other genes not being expressed are shut down by this genetic process of DNA methylation.” The rate of methylation in the suicide brains was found to be nearly ten times that of the control group, and the gene being shut down was a neurotransmitter receptor that plays a major role in regulating behavior. John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments, “This is exciting new evidence that genetic and environmental factors may interact to produce specific and long-lasting modifications in brain circuits. Further, these modifications may shape the course of one’s life in extremely important ways, including increasing the risk for major depressive disorder and perhaps suicide.”
“The whole idea that the genome is so malleable in the brain is surprising, because brain cells don’t divide. You get dealt your neurons at the start of life, so the idea that there are still epigenetic mechanisms going on is pretty unusual,” adds Poulter. The authors note that these observations open an entirely new avenue of research and potential therapeutic interventions.
Notes to Editors
The article is “GABAA Receptor Promoter Hypermethylation in Suicide Brain: Implications for the Involvement of Epigenetic Processes” by Michael O. Poulter, Lisheng Du, Ian C.G. Weaver, Miklós Palkovits, Gábor Faludi, Zul Merali, Moshe Szyf, and Hymie Anisman. Dr. Poulter is affiliated with the Molecular Brain Research Group, Robarts Research Institute, Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada. Dr. Poulter is also affiliated with, along with Drs. Merali and Anisman, the Institute of Neuroscience, Department of Psychology, Carleton University, Ottawa, Ontario, Canada. Dr. Merali, along with Dr. Du, is also from the Departments of Psychology and Psychiatry, University of Ottawa Institute of Mental Health Research, Ottawa, Ontario, Canada. Drs. Weaver and Szyf are with the Department of Pharmacology and Therapeutics (ICGW, MS), McGill University, Montreal, Quebec, Canada. Dr. Palkovits is affiliated with the Neuromorphological and Neuroendocrine Research Laboratory (MP), Hungarian Academy of Sciences and Semmelweis University, and Dr. Faludi is with the Department of Clinical and Theoretical Mental Health, Semmelweis University, Budapest, Hungary. The article appears in Biological Psychiatry, Volume 64, Issue 8 (October 15, 2008), published by Elsevier.
The authors’ disclosures of financial and conflicts of interests are available in the article. Dr. Krystal's disclosures of financial and conflicts of interests are available here.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at (215) 239-3674 or firstname.lastname@example.org to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+1 215 239 3674